Self Reported Stressful Life Events and Exacerbations in Multiple Sclerosis:Prospective Study
BMJ 327:646-649, Beljevac,D.,et al, 2003
Multiple Sclerosis Presenting as Lower Motor Neuron Wasting and Weakness of the Distal Upper Extremity
Neurol 61:1303-1304, Chong,P.S.T.,et al, 2003
Three Subsequent Single Doses of Gadolinum Chelate for Brain MR Imaging in Multiple Sclerosis
AJNR 24:658-662, Sardanelli,F.,et al, 2003
Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003
Acupuncture in Clinical Neurology
The Neurologist 9:137-148, Rabinstein,A.A. &Shulman,L.M., 2003
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
The Outcome of Neurology Outpatients with Medically Unexplained Symptoms: A Prospective Cohort Study
JNNP 74:897-900,842, Carson,A.J.,et al, 2003
Cognitive Presentation of Multiple Sclerosis: Evidence for a Cortical Variant
JNNP 74:872-877, Zarei,M.,et al, 2003
A Randomized Controlled Study of the Acute and Chronic Effects of Cooling Therapy for MS
Neurol 60:1955-1960, NASA/MS Cooling Study Group, 2003
A Longitudinal Study of Brain Volume Changes in Normal Aging Using Serial Registered Magnetic Resonance Imaging
Arch Neurol 60:989-994, Scahill,R.I.,et al, 2003
High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003
Autoantibodies to Glutamic Acid Decarboxylase in Downbeat Nystagmus
JNNP 74:998-999, Antonini,G.,et al, 2003
Constipation in Neurological Diseases
JNNP 74:13-19, Winge,K.,et al, 2003
New Diagnostic Criteria for Multiple Sclerosis
Neurol 60:27-30,6, Tintore,M.,et al, 2003
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 348:14-23, Miller,D.H.,et al, 2003
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Rasmussen's Encephalitis
Neurol 60:422-425, Granata,T.,et al, 2003
Hippocampal Sclerosis Is a Progressive Disorder: A Longitudinal Volumetric MRI Study
Ann Neurol 53:413-416, Fuerst,D.,et al, 2003
Neuromyelitis Optica:What It Is and What It Might Be
Lancet 361:889-890, Weinshenker,B.G., 2003
Multiple Sclerosis and Epstein-Barr Virus
JAMA 289:1533-1536, Levin,L.I.,et al, 2003
New T2 Lesions Enable an Earlier Diagnosis of Multiple Sclerosis in Clinically Isolated Syndromes
Ann Neurol 53:673-676, Dalton,C.M.,et al, 2003
Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002
Copaxone's Effect on MRI-Monitored Disease in Relapsing MS is Reproducible and Sustained
Neurol 59:1284-1286, Wolinsky,J.S.,et al, 2002
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Immunization and MS
Neurol 59:1837-1843, Rutschmann,O.T.,et al, 2002
Course and Prognosis in Early-Onset MS
Neurol 59:1922-1928, Simone,I.L., etla, 2002
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
MRI Predictors of Early Conversion to Clinically Definite MS in the CHAMPS Placebo Group
Neurol 59:998-1005, CHAMPS Study Group, 2002
A Randomized, Double-Blind, Dose-Comparison Study of Weekly Interferon B-1a in Relapsing MS
Neurol 59:1507-1517,1482, Clanet,M.,et al, 2002
Randomized, Comparative Study of Interferon B-1a Treatment Regimens in MS
Neurol 59:1496-1506,1482, Panitch,H.,et al, 2002
Acute Disseminated Encephalomyelitis
Neurol 59:1224-1231, Tenembaum,S.,et al, 2002
Therapy-Related Acute Myeloblastic Leukemia After Mitoxantrone Treatment in a Patient with MS
Neurol 59:954-955, Brassat,D.,et al, 2002
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Prognosis for Gross Motor Function in Cerebral Palsy
JAMA 288:1357-1363,1399, Rosenbaum,P.L., et al, 2002
A Blinding Combination
Lancet 360:1220, Matthews,B.N.,et al, 2002
Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Assessment of Normal-Appearing White and Gray Matter in Patients with Primary Progressive Multiple Sclerosis
Arch Neurol 59:1406-1412, Rovaris,M.,et al, 2002
Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002
Progressive Ventricular Enlargement in Patients with Clinically Isolated Syndromes is Associated with the Early Development of Multiple Sclerosis
JNNP 73:141-147, Dalton,C.M.,et al, 2002
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Refractory Status Epilepticus
Arch Neurol 59:205-210,188, Mayer,S.A.,et al, 2002
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002
Predictors of Functional Disability and Mortality After Status Epilepticus
Neurol 58:139-142, Claassen,J.,et al, 2002
Sandlike Appearance of Virchow-Robin Spaces in Early Multiple Sclerosis:A Novel Neuroradiologic Marker
AJNR 23:376-380, Achiron,A.&Faibel,M., 2002